Viemed Healthcare, Inc. (VMD) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Viemed Healthcare, Inc. (VMD) stock forecast summary
Our AI ranks Viemed Healthcare, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Viemed Healthcare, Inc. is a small-cap company with a market capitalization of $366M. It ranks number 6 by market capitalization among the 11 Services-Misc Health & Allied Services, NEC issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for VMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, VMD included.
Follow VMD freeVMD price chart and AI forecast
How VMD ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Viemed Healthcare, Inc. (VMD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Misc Health & Allied Services, NEC peers listed below that report each metric.
Valuation & Market
| Metric | VMD | Rank |
|---|---|---|
| Market Cap | $366M | 6/11 |
| P/E Ratio | 25.25x | 3/5 |
| P/B Ratio | 2.54x | 5/7 |
| EPS | $0.36 | – |
| Book Value/Share | $3.78 | – |
| Revenue/Share | $7.92 | – |
| FCF/Share | $0.77 | – |
Profitability & Margins
| Metric | VMD | Rank |
|---|---|---|
| ROE | 10.1% | 3/7 |
| ROA | 7.1% | 2/10 |
| ROIC | 14.6% | 3/8 |
| Gross Margin | 57.4% | 3/6 |
| Operating Margin | 7.5% | 4/9 |
| Net Margin | 4.8% | 5/10 |
| EBT Margin | 7.0% | 5/10 |
| Tax Rate | 29.1% | – |
Financial Health
| Metric | VMD | Rank |
|---|---|---|
| Current Ratio | 1.13x | 6/11 |
| Quick Ratio | 1.02x | 4/5 |
| D/E Ratio | 0.40x | 6/9 |
| Financial Leverage | 1.42x | 6/9 |
| Interest Coverage | 27.2x | 3/12 |
| Working Capital | $6M | 6/11 |
Cash Flow
| Metric | VMD | Rank |
|---|---|---|
| Operating Cash Flow | $61M | 5/11 |
| Free Cash Flow | $29M | 4/7 |
| Capital Spending | -$32M | 5/7 |
| OCF Growth YoY | 41.9% | 1/7 |
| FCF/Sales | 9.7% | 4/7 |
| CapEx/Sales | 10.5% | 2/7 |
Operational Efficiency
| Metric | VMD | Rank |
|---|---|---|
| Asset Turnover | 1.48x | 4/9 |
| Receivables Turnover | 9.4x | 3/9 |
| Inventory Turnover | 24.4x | – |
| Fixed Assets Turnover | 3.9x | 5/8 |
| Days Sales Outstanding | 39 days | 7/9 |
| Days Inventory | 15 days | – |
Income Statement
| Metric | VMD | Rank |
|---|---|---|
| Total Revenue | $301M | 5/9 |
| Operating Income | $22M | 4/10 |
| Net Income | $14M | 4/10 |
| R&D Expense | $2M | 4/6 |
| SG&A Expense | $136M | 4/6 |
| Cost of Goods Sold | $128M | 4/8 |
Dividend & Shareholder Information
| Metric | VMD | Rank |
|---|---|---|
| Shares Outstanding | 38M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $54M | 26.4% of assets |
| Cash & Short-term Investments | $11M | 5.2% of assets |
| Accounts Receivable | $32M | 15.8% of assets |
| Inventory | $5M | 2.6% of assets |
| Total Liabilities | $58M | 28.5% of assets |
VMD quarterly financials and insider trading
Viemed Healthcare, Inc. (VMD) industry peers
Companies classified under the same SEC industry code as Viemed Healthcare, Inc. (Services-Misc Health & Allied Services, NEC): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| VMD Viemed Healthcare, Inc. | ▲ | $366M |
| DVA Davita Inc. | ▶ | $11.62B |
| FMS Fresenius Medical Care Ag | ▼ | $5.89B |
| SHC Sotera Health Co | ▼ | $5.20B |
| PGNY Progyny, Inc. | ▶ | $2.10B |
| AGL Agilon Health, Inc. | ▶ | $1.44B |
| PARK Park Dental Partners, Inc. | ▲ | $96M |
| MRAI Marpai, Inc. | ▲ | $87M |
| CCEL Cryo Cell International Inc | ▲ | $35M |
| PFHO Pacific Health Care Organization Inc | ▲ | $12M |
| MGRX Mangoceuticals, Inc. | ▶ | $8M |
| BRTX Biorestorative Therapies, Inc. | ▶ | N/A |
| NIVF Newgenivf Group Ltd | ▼ | N/A |
Where VMD sits on the market map
Viemed Healthcare, Inc. (VMD) stock news
Loading...
Viemed Healthcare, Inc. (VMD) stock forecast FAQ
What is the Viemed Healthcare, Inc. (VMD) stock forecast?
Our AI ranks Viemed Healthcare, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Viemed Healthcare, Inc. stock predictions?
A per-ticker accuracy statistic for VMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Viemed Healthcare, Inc. forecasts updated?
Viemed Healthcare, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Viemed Healthcare, Inc.'s industry peers?
13 issuers in our coverage, VMD included, share the SEC industry code Services-Misc Health & Allied Services, NEC. The largest are: Davita Inc. (DVA), Fresenius Medical Care Ag (FMS), Sotera Health Co (SHC), Progyny, Inc. (PGNY), Agilon Health, Inc. (AGL), Park Dental Partners, Inc. (PARK).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.